David Y T Chen
Overview
Explore the profile of David Y T Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
2444
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geynisman D, Abbosh P, Ross E, Zibelman M, Ghatalia P, Anari F, et al.
J Clin Oncol
. 2024 Dec;
43(9):1113-1122.
PMID: 39680823
Purpose: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Mutations in DNA damage repair genes are associated with pathologic...
2.
Lee P, Ruth K, Lee D, Hallman M, Chen D, Wong J, et al.
Brachytherapy
. 2024 Jul;
23(5):559-568.
PMID: 39060143
Purpose: We aim to investigate perioperative and subacute postoperative complications in patients undergoing LDR or HDR monotherapy for prostate cancer. We hypothesize a low rate of complications, and a favorable...
3.
Esnaola N, Chelluri R, Castellanos J, Altman A, Chen D, Chu C, et al.
Ann Surg
. 2024 Jul;
281(3):395-403.
PMID: 39045699
Objective: To evaluate the efficacy of risk-based, protocol-driven management versus usual management after elective major cancer surgery to reduce 30-day rates of postoperative death or serious complications (DSCs). Background: Major...
4.
George A, Miocinovic R, Patel A, Lomas D, Correa A, Chen D, et al.
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927884
The PRESERVE study (NCT04972097) aims to evaluate the safety and effectiveness of the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer (PCa). The NanoKnife uses irreversible...
5.
Morgan T, Boorjian S, Buyyounouski M, Chapin B, Chen D, Cheng H, et al.
J Urol
. 2024 Feb;
211(4):509-517.
PMID: 38421253
Purpose: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a...
6.
Morgan T, Boorjian S, Buyyounouski M, Chapin B, Chen D, Cheng H, et al.
J Urol
. 2024 Feb;
211(4):526-532.
PMID: 38421252
Purpose: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a...
7.
Morgan T, Boorjian S, Buyyounouski M, Chapin B, Chen D, Cheng H, et al.
J Urol
. 2024 Feb;
211(4):518-525.
PMID: 38421243
Purpose: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a...
8.
Schober J, Ginsburg K, Kutikov A, Cho E, Loecher M, Strauss D, et al.
BJU Int
. 2023 Sep;
133(2):206-213.
PMID: 37667554
Objective: To determine whether a simple point-of-care measurement system estimating renal parenchymal volume using tools ubiquitously available could be used to replace nuclear medicine renal scintigraphy (NMRS) in current clinical...
9.
Demidova E, Serebriiskii I, Vlasenkova R, Kelow S, Andrake M, Hartman T, et al.
BMC Genomics
. 2023 Jul;
24(1):388.
PMID: 37430226
No abstract available.
10.
Schober J, Braun A, Ginsburg K, Bell S, Castro Bigalli A, Chen M, et al.
J Urol
. 2023 Jun;
210(3):438-445.
PMID: 37378576
Purpose: Technetium-99m-sestamibi single-photon emission CT/x-ray CT is an emerging clinical tool to differentiate oncocytic tumors from renal cell carcinomas. We report data from a large institutional cohort of patients who...